

Editors' Disclosures of Potential Conflicts of Interest

The editors have disclosed their potential conflicts of interest during 2007 in the table below. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Disclosures of Potential Conflicts of Interest in the Information for Contributors. Some editors do not have conflicts to disclose.

Member	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Douglas W. Blayney	National Cancer Center Network (M,U) University of Michigan Comprehensive Cancer Center (M,C)	Amgen, Inc (M,C) Biogen/IDEC (M,C) Eisai Pharmaceuticals (M,C) Eli Lilly & Company (M,C) Gerson Lehrman Group (M,C) Medacorp (M,C)	Community Oncology Advisory Group (B)	Clinical Oncology Advisory Group (M) Eli Lilly and Company (M)	Amgen, Inc. (M) BMS -- Data Safety Monitoring Committee (M)		
Gary H. Lyman							
Therese M. Mulvey		MGI, Imclone, Eisai (M,C)					

Disclosure Codes (M) myself, (I) immediate family member, (B) myself and immediate family, (C) compensated, (U) uncompensated